Angiosarcoma of the Retroperitoneum: Report on a Patient Treated with Sunitinib by Yoo, Changhoon et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2009, Article ID 360875, 4 pages
doi:10.1155/2009/360875
Case Report
A ngio s a r c o mao ft heR etr o pe rit o ne um:
Reporton a Patient Treated with Sunitinib
ChanghoonYoo,1 Jeong-Eun Kim,1 Shin-Kyo Yoon,1 SongCheolKim,2 Jin-Hee Ahn,3
Tae Won Kim,3 Cheolwon Suh,3 andJae-LyunLee3
1Department of Internal medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu,
Seoul 138-736, South Korea
2Department of Surgery, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu,
Seoul 138-736, South Korea
3Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu,
Seoul 138-736, South Korea
Correspondence should be addressed to Jae-Lyun Lee, jaelyun@amc.seoul.kr
Received 13 January 2009; Accepted 20 April 2009
Recommended by Cyril Fisher
A 52 year-old woman presented with an incidentally detected retroperitoneal angiosarcoma and multiple hepatic metastases.
After chemotherapy with weekly paclitaxel and doxorubicin, angiosarcoma had progressed rapidly. Because few chemotherapeutic
options were available for her, sunitinib (37.5mg/day, daily) as a salvage regimen was administered. Although sunitinib was
interrupted after two weeks due to hematologic abnormalities, some metastatic nodules were regressed. Therefore, sunitinib
was recommenced at a reduced dose (25mg/day, daily). Serial computed tomography scans showed variable response in each
tumor, however, sunitinib at least delayed tumor progression, compared to previous chemotherapy. With this case report,
we suggest sunitinib may be eﬀective against angiosarcomas. When sunitinib is administered to patients with angiosarcomas,
hematologic abnormalities should be monitored frequently as severe hematologic toxicity may be caused either by sunitinib per se
or angiosarcoma.
Copyright © 2009 Changhoon Yoo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Angiosarcomas are rare subtypes of soft tissue sarcomas
originating from the vascular endothelium, and commonly
occur in skin and soft tissues [1]. The clinical presentation
of angiosarcomas is heterogeneous and multidisciplinary
treatment is often necessary [2]. To treat localized disease,
surgery followed by radiotherapy is a standard modality. In
patients with advanced disease, paclitaxel- and doxorubicin-
based regimens have been valuable [1, 2]. However, the
prognosis of patients with advanced angiosarcoma remains
poor, particularly when the condition progresses to a stage
where cytotoxic agents are not eﬀective [2, 3]. Today, with
the development of drugs targeted to particular molecules
involved in disease, several subtypes of sarcomas have been
successfully treated and a number of clinical trials are
ongoing [4]. Herein, we report on a patient with advanced
angiosarcoma who responded favorably to sunitinib after
failure of paclitaxel and doxorubicin.
2.CaseReport
A52year-oldwomanpresentedwithanincidentallydetected
retroperitoneal mass and multiple liver nodules. Her ini-
tial computed tomography (CT) and positron emission
tomography (PET) scans showed a huge retroperitoneal
mass with direct invasion into the spleen, pancreas tail,
and stomach, and three metastatic hepatic nodules. The
size of the retroperitoneal mass was 12.5 × 10cm and the
dimensions of the hepatic metastases were 4.4 × 4.1cm
in segment IV, and 2.5 × 1.9cm and 1.2 × 1.1cm in the
right posterior segment. Percutaneous needle biopsy of2 Sarcoma
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Figure 1: Serial CT scans show variable response in retroperitoneal mass (arrowhead), multiple nodules of left hepatic lobe and two nodules
(arrows) of right posterior lobe. (a) At initial presentation, (b) after one cycle of weekly paclitaxel, (c) after two cycles of doxorubicin, (d)
after 3 months of sunitinib
a hepatic nodule was performed. In histology, irregular and
sinusoidal vascular proliferation, atypical endothelial lining,
and undiﬀerentiated tumor cells were noted. These ﬁndings
were consistent with angiosarcoma. This is supported by
immunohistochemical study that shown tumor cells were
positive for CD 31 and CD34.
Weekly paclitaxel (80mg/m2, on days 1, 8, 15, and 22,
every 6 weeks) was administered as ﬁrst-line chemotherapy.
Our patient tolerated this regime well; no signiﬁcant toxic-
ities were observed. After one cycle of paclitaxel, a CT scan
(Figure 1(b)) revealed an increase in size of the three hepatic
nodules and multiple new hepatic metastases. Therefore,
we administered two cycles of second-line chemotherapy
employing doxorubicin (60mg/m2, day 1, every 3 weeks).
In a follow-up CT scan (Figure 1(c)), the diameter of
retroperitoneal mass was somewhat increased from 12.8cm
to 13.9cm. However, twelve hepatic metastatic nodules
were newly developed and the size of previously detected
hepatic nodules was increased within two months. The
disease status was rapidly deteriorated and we had few
chemotherapeutic options, but our patient’s general perfor-
mance was suﬃciently good to allow us to consider further
chemotherapy.
After a full and careful discussion with the patient,
we administered sunitinib (37.5mg/day, daily) as a salvage
regimen. After 2 weeks of sunitinib, the patient presented
to the clinic with severe asthenia, and chemotherapy was
interrupted. A laboratory investigation revealed grade 4
thrombocytopenia, grade 3 anemia, fragmented RBCs in
the peripheral blood smear, and decreased levels of both
serum haptoglobin and ﬁbrinogen. Prothombin time was
within normal limits. These data supported a diagno-
sis of microangiopathic hemolytic anemia (MAHA). The
hematologic abnormalities were suggestive of the Kasabach-
Merritt phenomenon (KMP), except that coagulopathy was
absent. One month later, the thrombocytopenia and anemia
had regressed. At that time, a CT scan yielded interesting
ﬁndings. Some of the numerous scattered hepatic nodules
had disappeared, whereas others showed no change in
size, and the size of the retroperitoneal mass had also
decreased, with evidence of internal necrosis, although two
hepatic masses in the right posterior segment had progressed
slightly. When we considered the prolonged interruption
to treatment caused by toxicity, and the rapid rate of
progressionpriortotheintroductionofsunitinib,weformed
the view that sunitinib was active against our patient’s
tumors. Therefore, we recommenced sunitinib treatment,
but at a reduced dose (25mg/day, daily). Although grade 2
thrombocytopenia and MAHA reoccurred, these toxicities
were less severe than before. On monthly CT scans, some
hepatic metastases and the retroperitoneal mass responded
to sunitinib. However, two hepatic metastases of the right
posterior segment further progressed; it was thus diﬃcult
to interpret any overall chemotherapeutic eﬀect of sunitinib.
To evaluate any antitumor activity on the two hepatic
m a s s e s ,g r o s st u m o rv o l u m ew a sm e a s u r e do ns e r i a lC T
scans (Figure 1) and the volume doubling times (VDT)
between each chemotherapy regime were calculated, using
the equation: VDT = [t × log2]/log[Vt/Vo], where t is
the interval in days between two scans, and Vo and Vt are
tumor volumes at the previous and current examination,
respectively. The hepatic mass tumors had VDT values
of 16 days on paclitaxel, 66 days on doxorubicin, and
145 days on sunitinib. We thus concluded that sunitinib
could delay tumor progression and the treatment was
continued.Sarcoma 3
After an additional 3 months of sunitinib therapy, recur-
rent hematologic toxicities associated with MAHA/KMP and
concomitant deterioration of the patient’s general condition
caused chemotherapy to be interrupted. Two months later,
the patient died of tumor invasion to her heart and inferior
vena cava, about 11 months after initial diagnosis.
3. Discussion
Angiosarcomas are derived from vascular endothelial cells
a n da c c o u n tf o rl e s st h a n2 %o fs o f tt i s s u es a r c o m a s
[3]. The median survival time of patients with advanced
angiosarcomas is about 7-8 months [2, 5]. Larger tumor
size (>5cm), location in the retroperitoneum, and advanced
disease,areassociatedwithpoorprognosis[6].Doxorubicin-
based chemotherapy has been considered the standard
treatment for patients with advanced angiosarcomas as well
as for those with other soft tissue sarcomas [2, 6, 7]. Recent
reports have shown that paclitaxel is also eﬀective against
angiosarcoma [5, 7–10]. However, few clinical drug trials on
angiosarcoma patients have been carried out because of the
low incidence of the disease; hence very little information on
treatment is available, especially when the disease progresses
after a short period of response to or stabilization with
doxorubicin or paclitaxel.
Recently, tyrosine kinase inhibitors (TKIs) have emerged
as novel agents in the treatment of soft tissue sarcomas
[4]. There are no published clinical data on the use
of TKIs as therapy for angiosarcoma patients. However,
angiosarcomas originate from vascular endothelial tissues
andexpressproangiogenicfactorsincludingVEGF[4].These
ﬁndings suggest a possible role for TKIs in angiosarcoma
treatment, and several TKIs directed against angiosarcomas
are currently in clinical trials [4, 11]. Sunitinib, recently
approved for patients with imatinib-refractory GIST and
advanced renal cell carcinoma, inhibits several tyrosine
kinases and has antiangiogenic activity. The drug may thus
be active against vascular endothelial cell-derived or vascular
endothelial cell-dependent cancers [4, 11].
During treatment with sunitinib, our patient suﬀered
from severe thrombocytopenia and MAHA. Although suni-
tinib suppresses bone marrow function, and a single case
report of sunitinib-induced thrombotic thrombocytopenia
purpura has appeared [12], it is diﬃcult to conclude that the
reportedhematologicabnormalitieswerecausedbysunitinib
a l o n e ,b e c a u s es u c hp r o b l e m sh a v eb e e nr e p o r t e di no n l y
very few GIST or renal cell carcinoma patients enrolled in
large phase III clinical studies. The occurrence of severe
anemia, and thrombocytopenia with laboratory features of
MAHA, might be in part attributable to KMP, a syndrome
associated with vascular tumors, which shows features
similar to those of MAHA and consumptive coagulopathy
[12–14].
In this case report, our patient had advanced angiosar-
coma and her clinical features suggested the worst possible
outcome [6]. The tumor was progressing rapidly and
showed no response to conventional chemotherapy. We
used sunitinib as a last resort. The overall response to
sunitinib was hard to evaluate, but we observed dramatic
responses in some hepatic nodules and the retroperitoneal
mass, and decreased VDTs of two hepatic metastases in the
right posterior segment. Eventually, her disease did progress.
We suggest that individual tumor nodules may respond
diﬀerently to sunitinib. Tumor nodules may gain or lose
sunitinib sensitivity by operation of an unknown molecular
mechanism whereas other nodules may show constitutive
sunitinib sensitivity, as found in the polyclonal evolution of
GIST treated with imatinib [15].
In conclusion, this is the ﬁrst case report indicating
that sunitinib may be eﬀective against angiosarcomas. When
sunitinib is administered to patients with angiosarcomas,
hematologic abnormalities should be monitored frequently
as severe hematologic toxicity may be caused either by
sunitinib per se or angiosarcoma. Further studies are needed
to explore sunitinib eﬃcacy in angiosarcoma treatment.
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